Bionano Genomics, Inc. (BNGO) Financial Statements (2025 and earlier)

Company Profile

Business Address 9540 TOWNE CENTRE DRIVE
SAN DIEGO, CA 92121
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 3826 - Laboratory Analytical Instruments (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments66,771113,186250,61238,44917,31116,523
Cash and cash equivalent17,9485,09124,57138,44917,31116,523
Short-term investments48,823108,095226,041   
Restricted cash and investments35,117     
Receivables9,6617,4965,3212,7756,3344,514
Inventory, net of allowances, customer advances and progress billings27,60229,76112,3873,3163,4441,069
Inventory27,60229,76112,3873,3163,4441,069
Prepaid expense1,1021,6321,7461,788712535
Other current assets9762,4122,348462457384
Other undisclosed current assets(1,111)2,811    
Total current assets:140,118157,298272,41446,78928,25823,025
Noncurrent Assets
Finance lease, right-of-use asset, after accumulated amortization3,5033,7073,926  
Operating lease, right-of-use asset5,6337,2226,691  
Property, plant and equipment23,34518,02910,3184,9101,9501,777
Intangible assets, net (including goodwill)33,974118,43283,0028,647  
Goodwill  77,28956,1607,173  
Intangible assets, net (excluding goodwill)33,97441,14326,8421,475  
Restricted cash and investments400400    
Other noncurrent assets7,4312,414749103  
Total noncurrent assets:74,286150,204104,68613,6601,9501,777
TOTAL ASSETS:214,404307,502377,10060,45030,20824,802
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities18,47323,08619,3908,5285,9254,252
Accounts payable10,38412,5349,6962,9302,6991,352
Accrued liabilities8,08910,5529,6945,5993,2252,900
Deferred revenue783871684416357
Debt272285299 20,085 
Business combination, contingent consideration, liability  9,382    
Other undisclosed current liabilities80,5002,2601,467  271
Total current liabilities:100,02835,88421,8408,94426,3674,523
Noncurrent Liabilities
Long-term debt and lease obligation3,5853,6198,93016,326 9,029
Long-term debt, excluding current maturities    16,326 9,029
Finance lease, liability3,5853,6193,642  
Liabilities, other than long-term debt14,63418,60114698227808
Deferred revenue15412714698183
Other liabilities     44808
Operating lease, liability3,5905,5045,288  
Business combination, contingent consideration, liability 10,89012,970    
Other undisclosed noncurrent liabilities   9,066  304
Total noncurrent liabilities:18,21922,22018,14216,42322710,142
Total liabilities:118,24758,10439,98225,36726,59414,665
Equity
Equity, attributable to parent96,157249,398337,11835,0823,61410,137
Common stock 530291931
Additional paid in capital677,337599,207553,747178,747106,18882,899
Accumulated other comprehensive income (loss)23(1,124)(539)   
Accumulated deficit(581,208)(348,715)(216,119)(143,684)(102,577)(72,762)
Total equity:96,157249,398337,11835,0823,61410,137
TOTAL LIABILITIES AND EQUITY:214,404307,502377,10060,45030,20824,802

Income Statement (P&L) ($ in thousands)

12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Revenues36,11627,80217,9818,50310,13012,001
Cost of revenue
(Cost of Product and Service Sold)
(26,550)(21,857)(14,107)(5,730)(6,768)(8,711)
Gross profit:9,5665,9453,8742,7733,3613,289
Operating expenses(224,811)(137,643)(80,975)(41,324)(29,236)(23,704)
Other undisclosed operating loss      
Operating loss:(215,245)(131,698)(77,101)(38,551)(25,875)(20,415)
Nonoperating income (expense)(17,186)986(1,051)(2,526)(3,919)1,934
Other nonoperating income (expense)3,449(223)(59)(7)(299)(676)
Interest and debt expense(5,119)(298)(2,076)(2,519)(1,333)(342)
Loss from continuing operations before equity method investments, income taxes:(237,550)(131,010)(80,228)(43,596)(31,128)(18,823)
Other undisclosed income from continuing operations before income taxes5,1192982,0762,5191,333342
Loss from continuing operations before income taxes:(232,431)(130,712)(78,152)(41,077)(29,794)(18,481)
Income tax expense (benefit)(62)(1,884)5,717(29)(21)(16)
Loss from continuing operations:(232,493)(132,596)(72,435)(41,106)(29,815)(18,496)
Loss before gain (loss) on sale of properties:(72,435)(41,106)(29,815)(18,496)
Net loss available to common stockholders, diluted:(232,493)(132,596)(72,435)(41,106)(29,815)(18,496)

Comprehensive Income ($ in thousands)

12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Net loss:(232,493)(132,596)(72,435)(41,106)(29,815)(18,496)
Comprehensive loss:(232,493)(132,596)(72,435)(41,106)(29,815)(18,496)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent1,147(585)(539)   
Comprehensive loss, net of tax, attributable to parent:(231,346)(133,181)(72,974)(41,106)(29,815)(18,496)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: